MedPage Today on MSN
Add-On Multicancer Early Detection Test Promising Across Various Cancer Types
BERLIN -- Adding a test that predicts cancer signal origin to single standard of care (SoC) screening substantially increased ...
“Our findings show that RNA-based testing can uncover hidden risks in multiple myeloma that DNA tests alone miss,” study ...
In recent years, the market size for cell-free DNA (cfDNA) kits has expanded swiftly. This market is projected to increase from $1.60 billion in 2024 to $1.80 billion in 2025, marking a compound ...
Scientists have long suspected connections between heredity and disease, dating back to Hippocrates, who observed certain ...
By examining genomic variation more closely, scientists can now identify new disease connections with greater speed and accuracy. For centuries, scientists have recognized that certain illnesses can ...
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 ...
When Erica Barnell was an MD/PhD student at Washington University in St. Louis, she met a woman who had stage four colorectal cancer (CRC). The woman was only 52 years old—more than a decade younger ...
(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback